BioClinica, Inc. Releases OnPoint CTMS to Meet Growing Market Demand

BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the release of BioClinica OnPoint CTMS and noted a surge in clinical trial management system (CTMS) demand. OnPoint is the new release of the CTMS platform that BioClinica acquired from TranSenda in 2010.

"A quiet transformation of clinical study architectures is occurring in the industry through the increased use of standard collaboration tools for clinical study management and regulatory document management,” says Gartner Research Vice President Steve Lefebure. "Life science companies are seeking to leverage existing infrastructure, support collaboration, and create flexibility. Solutions that leverage both industry standard collaboration tools and office automation software while providing comprehensive clinical study management capabilities present significant advantages in this environment.”

BioClinica OnPoint CTMS helps sponsors of clinical trials and CROs to efficiently access, share, and analyze operational trial data by leveraging the power and ease of use of the Microsoft^® SharePoint standard collaboration and office automation tools. BioClinica's patent-pending data interchange technology eases the acquisition of operational data from multiple sources in real-time. OnPoint’s tight integration with SharePoint enables users to interact with the system via Microsoft Office applications (Outlook, Excel, Word, etc.), speeding user adoption and compliance. Organizations find they can decrease their cost of ownership for large implementations using SharePoint’s proven scalability to manage millions of documents.

"We are experiencing extremely strong interest for OnPoint CTMS,” said Peter Benton, President of eClinical Solutions for BioClinica. "So far in this quarter we have already received contract awards from four pharma and device companies that range from mid to large in size. The combination of features, value and fast implementation – augmented by OnPoint’s out-of-the-box integration with SharePoint – is changing market perceptions of CTMS’ utility and cost-effectiveness.”

The new release of BioClinica OnPoint CTMS includes full support for the advanced features of SharePoint 2010. For organizations who desire to minimize infrastructure investment, BioClinica also offers hosting options for OnPoint. OnPoint has been selected by clinical trial sponsors and CROs after comprehensive market assessments and evaluations that have demonstrated not only the system’s capabilities, but have also delivered high satisfaction ratings and a high level of user adoption.

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com

Certain matters discussed in this press release are "forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.